Log In
Print
BCIQ
Print
Print this Print this
 

VE-202

  Manage Alerts
Collapse Summary General Information
Company Vedanta Biosciences Inc.
DescriptionOral formulation of live Clostridium bacteria
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPreclinical
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat inflammatory bowel disease (IBD)
Regulatory Designation

Partner

Johnson & Johnson


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$241.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today